KALARIS THERAPEUTICS, INC. Debt Securities, Available-for-sale
KALARIS THERAPEUTICS, INC. (KLRS) had Debt Securities, Available-for-sale of $50.37 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale $50.37M.
- 2026-03-31: Debt Securities, Available-for-sale $70.44M.
- 2025-12-31: Debt Securities, Available-for-sale $19.93M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $50.37M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $70.44M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $19.93M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |